Comment restaurer la compétitivité de la recherche française en biologie-santé ?

Maryaline Catillon

Revue d'économie financière, 2021, vol. N° 143, issue 3, 123-142

Abstract: In 2000, France was fifth worldwide in biomedical research production. In 2020, France ranked ninth. Over the past ten years, both resources devoted to biomedical research in France and French scientific production declined compared to other leading countries. The currently planned increase in funding and reforms won't be enough to restore France competitiveness in biomedical research. In the international context, this article documents key developments over the past ten years, describes currently planned reforms, and suggests other evidence-based restorative measures: creating a quantitative and qualitative evaluation program for biomedical research to deepen understanding of the situation; imposing rules about coordination and maximum delays for decisions to the multiple agencies and organizations funding and managing biomedical research; developing training programs in research quality and reproducibility for doctors and scientists; subjecting clinical trial funding to methodological criteria; and fostering interdisciplinarity in higher education. Classification JEL : I11, I12, I14.

JEL-codes: I11 I12 I14 (search for similar items in EconPapers)
Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.cairn.info/load_pdf.php?ID_ARTICLE=ECOFI_143_0123 (application/pdf)
http://www.cairn.info/revue-d-economie-financiere-2021-3-page-123.htm (text/html)
free

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cai:refaef:ecofi_143_0123

Access Statistics for this article

More articles in Revue d'économie financière from Association d'économie financière
Bibliographic data for series maintained by Jean-Baptiste de Vathaire ().